Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study
Patients with newly diagnosed AML treated with Oral-AZA maintenance in clinical practice had prolonged remission and lower HCRU and costs than patients receiving no maintenance therapy. These findings underscore the clinical and economic value of Oral-AZA in clinical practice.
Authors
- Uma Borate (ORCID: https://orcid.org/0000-0002-4958-4962)
- Maria Strocchia
- Alberto Vasconcelos
- Thomas Prébet (ORCID: https://orcid.org/0000-0002-6872-625X)
- Ravi Potluri (ORCID: https://orcid.org/0000-0002-0509-2659)
- Jan Sieluk (ORCID: https://orcid.org/0000-0002-1833-0273)
- Karen Seiter (ORCID: https://orcid.org/0000-0003-3838-7901)
- Lona Gaugler
- Manoj Chevli
- Debasish Mazumder
Institutions
- New York Medical College (US)
- Bristol-Myers Squibb (United States) (US)
- The Ohio State University (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s12325-024-02947-1
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Bristol-Myers Squibb